Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from NYSE

3 Dividend Growth Stocks Analysts Are Upgrading for 2026

United Parcel Service, PepsiCo, and AbbVie are healthy dividend payers whose analyst trends support an outlook for price strength in 2026.

MarketBeat

3 Surging Stocks Just Got the Ultimate Stamp of Approval From the S&P 500

Comfort Systems USA, Carvana, and CRH will join the S&P 500 on Dec. 22 after standout 2025 performances driven by data centers and market share gains.

MarketBeat

This ETF Caught a Major Tailwind After the Fed’s Rate Cut

Following the Federal Reserve’s third and final interest rate cut of 2025, this financials sector ETF is poised to profit in the year ahead.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Nike Beats on Earnings But Struggles in China and Faces Tariffs

Apparel behemoth Nike just released its latest earnings as the firm works to revamp its business. Should investors buy in or look elsewhere for opportunities?

MarketBeat

Is the AI Boom a Bubble? These 2 Dividend Stocks Say No

Looking for AI stocks with staying power—or a hedge if the bubble bursts? Discover two dividend-paying companies built for both 2026 outcomes.

MarketBeat

Forget the Chips: 4 Industrial Plays for the AI Rebound

Investors can capture the next phase of the artificial intelligence boom by focusing on the industrial companies building the physical data center backbone.

MarketBeat

3 Cheap Dividend Stocks That Can Beat Inflation and Pay You to Wait

Energy, banking, and grocery stocks under $20 offer high-yield dividends that can help protect income from inflation through 2025 and into 2026.

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

Post 35% Surge, Analysts Eye More Upside in Copper Giant Freeport

Copper behemoth Freeport McMoRan is up more than 30% since its September fall. Analysts think shares could rise significantly more.

MarketBeat

4 Quantum Stocks to Watch as the Next Computing Revolution Unfolds

After the quantum computing industry faced some fall turbulence, investors might be looking to narrow exposure. These are some of the top firms to consider.

MarketBeat

Southwest Airlines and TJX Hit New 52-Week Highs: Which Is More Likely to Fly Higher in 2026 and beyond?

There were 56 new 52-week highs on the NYSE on Tuesday. Two of them were Southwest Airlines and TJX Companies. While both are flying high heading into the new year, only one is worth owning in 2026 and beyond.

Barchart

Massive Breakout in Industrials: 3 Must-Watch Stocks Now

The industrials sector is showing signs of leadership, with XLI breaking out of a lengthy consolidation and outperforming the broader market in the short term.

MarketBeat

David Tepper Offloads Intel, Slashes UnitedHealth Stake in Q3 to Buy This Lesser-Known Stock

In Q3, Appaloosa's David Tepper sold his entire stake in Intel and reduced his UnitedHealth Group holdings by over 90% to invest $400 million in Whirlpool shares.

International Business Times UK

Smart Money Is Buying Auto Suppliers, Not Car Brands

Suppliers Magna and Autoliv offer deep value and steady income by building the essential infrastructure for every major car brand in the global market.

MarketBeat

3 AI Names With Big Buybacks: GEV, PSTG, and LSCC Signal Confidence

GEV, PSTG, and LSCC are three AI stocks lifting their buyback authorizations. After a massive 27% drop, PSTG's announcement is a clear signal of confidence.

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most

Healthcare behemoths, including the biggest name of them all, are increasing their dividends. Additionally, AMGN's dividend yield now sits solidly above 3%.

MarketBeat

Pfizer Adds to Its Big Bet on Weight Loss Drugs

A month after acquiring obesity biotech Metsera, Pfizer's expanding in the weight loss drug market after signing a licensing agreement for a weight loss pill.

MarketBeat

Financial Sector Breaks Out as Capital Rotates and Leadership Shifts

The financial sector has broken out of a multi-month consolidation, with XLF clearing $54 resistance, signaling renewed momentum and signs of sector leadership.

MarketBeat

3 Finance Stocks to Buy on Rising 10-Year Treasury Rates

Rising 10-year Treasury rates are creating new opportunities in financial stocks. See why JPMorgan, Morgan Stanley, and Prudential could outperform in 2026

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

4 Canadian Oil Stocks That Are Filling the Heavy Crude Gap

Discover four Canadian oil stocks benefiting from a tight heavy-crude market. Learn why CNQ, ENB, IMO, and SU may offer strong upside for investors

MarketBeat

Oracle Stock Hit Hard: Why Its AI Pipeline Could Drive a 2026 Rally

Oracle is on track for a robust rebound as its rapidly expanding RPO is converted into revenue and profits: December price weakness is a buying opportunity.

MarketBeat

Walmart’s NASDAQ Switch Could Change Everything for WMT Stock

Walmart joins the NASDAQ in a historic move, signaling its shift toward AI and automation leadership as WMT stock continues its strong long-term uptrend

Barchart

VICI Properties Hits a New 52-Week Low: Is It Time for Income Investors to Place a Bet?

The real estate investment trust owner of casinos and other hospitality real estate hit its 11th new 52-week low of the past 12 months. Here’s why Income investors should consider laying down a bet.

Benzinga

New Dividend ETF Launches Just As Fed Decision Looms — Is KDVD The SMID-Cap Play Investors Need?

Gabelli Funds launched the Keeley Dividend ETF (NYSE:KDVD), an actively managed fund targeting income and long-term appreciation through small- and mid-cap dividend payers, just as markets hover near record highs and investors brace for a highly anticipated Federal Reserve rate cut.

Benzinga

BioNTech-Bristol Drug Shows Hope For Breast Cancer Patients With Few Options

BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb Co. (NYSE:BMY) on Tuesday shared the first interim data from a global randomized Phase 2 trial of pumitamig (BNT327/BMS986545) plus chemotherapy for locally advanced/metastatic triple-negative breast cancer (TNBC) irrespective of PD-L1 expression levels.

Benzinga

Famous Footwear Parent Caleres Warns Of Pain From Tariffs And Weitzman Integration

Caleres, Inc. (NYSE:CAL) shares plunged after it reported third-quarter 2025 results, with consolidated sales rising 6.6% year over year to $790.1 million, topping the $759.1 million estimate.

1 … 31 32 33 34

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.